Making Decisions About Stopping Medicines for Well-Controlled Juvenile Idiopathic Arthritis: A Mixed-Methods Study of Patients and Caregivers.
Daniel B HortonJomaira SalasAleksandra WecMelanie KohlheimPooja KapadiaTimothy BeukelmanAlexis BoneparthKy HaverkampMelissa L MannionL Nandini MoorthySarah RingoldMarsha RosenthalPublished in: Arthritis care & research (2021)
When deciding whether to stop medicines whenever JIA is inactive, patients and caregivers weigh competing risks between disease activity and treatment. Based on our results, we suggest specific approaches for clinicians to perform shared decision-making regarding stopping medicines for JIA.
Keyphrases
- juvenile idiopathic arthritis
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- palliative care
- end stage renal disease
- rheumatoid arthritis patients
- ankylosing spondylitis
- ejection fraction
- peritoneal dialysis
- newly diagnosed
- chronic kidney disease
- prognostic factors
- clinical trial
- study protocol